Abstract
Idenix Pharmaceuticals Inc and Novartis AG are codeveloping valopicitabine dihydrochloride, a once-daily oral nucleoside for the potential treatment of HCV infection. In January 2005, a phase IIa clinical trial comparing valopicitabine dihydrochloride with pegylated IFN in treatment-naive HCV patients was ongoing, in addition to a phase IIb trial in patients that had previously failed pegylated IFN and ribavirin combination therapy. In January 2006, an international phase III trial in treatment-refractory patients was planned for the first half of the year, with a phase III trial in treatment-naive individuals planned for the second half of the year.
MeSH terms
-
Animals
-
Clinical Trials, Phase II as Topic
-
DNA-Directed RNA Polymerases / antagonists & inhibitors*
-
DNA-Directed RNA Polymerases / metabolism
-
Drugs, Investigational / chemistry
-
Drugs, Investigational / therapeutic use
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / therapeutic use*
-
Hepacivirus / drug effects*
-
Hepacivirus / enzymology
-
Hepacivirus / growth & development
-
Hepatitis C / drug therapy
-
Hepatitis C / virology
-
Humans
-
Molecular Structure
-
Pyrimidine Nucleosides / chemistry
-
Pyrimidine Nucleosides / therapeutic use*
Substances
-
Drugs, Investigational
-
Enzyme Inhibitors
-
Pyrimidine Nucleosides
-
DNA-Directed RNA Polymerases
-
valopicitabine